摘要
目的系统评价水飞蓟宾葡甲胺片治疗乙型肝炎、抗结核药物或其他药物所致肝损伤、非酒精性脂肪肝的疗效和安全性。方法检索国内外中英文数据库建库至2019年1月水飞蓟宾葡甲胺片治疗乙型肝炎、抗结核药物或其他药物所致肝损伤、非酒精性脂肪肝的文献,对符合纳入和排除标准的文献进行质量评价,采用Meta分析评价水飞蓟宾葡甲胺片治疗以上适应证的有效性、安全性。结果本研究共纳入文献27篇,共计4258例样本。水飞蓟宾葡甲胺片联合用药(联合恩替卡韦/苦参注射液、胶囊/复方丹参注射液/拉米夫定/异甘草酸镁/复方鳖甲软肝片)治疗乙型肝炎的ALT、AST、TBiL、ALB、LN、HA、PC-3、IV-C指标改善情况优于单独用药(水飞蓟宾葡甲胺片、恩替卡韦、拉米夫定),差异有统计学意义(P<0.05);水飞蓟宾葡甲胺片单独用药预防抗结核药物或其他药物所致肝损伤的临床疗效、肝损害发生人数、不良反应指标优于对照组(联苯双酯、肌苷片、肝泰乐、葡醛内酯、护肝宁、维丙肝单独用药或联合用药),差异有统计学意义(P<0.05);水飞蓟宾葡甲胺片单独用药治疗非酒精性脂肪肝的临床疗效优于对照组(化滞柔肝颗粒/葡醛内酯),差异有统计学意义(P<0.05)。结论水飞蓟宾葡甲胺片联合用药治疗乙型肝炎疗效明确,肝功能指标改善明显,安全性好。其在预防抗结核药物或其他药物所致肝损伤临床疗效亦有明显优势。
Objective To evaluate the efficacy and safety of Silybin meglumine tablets in the treatment of hepatitis B,Liver injury caused by anti-TB drugs or other drugs,and nonalcoholic fatty liver disease.Methods The literatures of Chinese and English databases from home and abroad were searched for the treatment of Hepatitis B,Liver injury caused by anti-TB drugs or other drugs,and nonalcoholic fatty liver disease to January 2019,and the quality of the literature in accordance with the inclusion and exclusion criteria was evaluated.To evaluate the efficacy and safety of Silybin meglumine tablets in the treatment of the above indications with meta-analysis.Results A total of 27 articles were included in the study,totaling 4258 samples.Combination of Silybin meglumine tablets(in combination with entecavir/matrine injection,capsule/compound salvia miltiorrhiza injection/lamivudine/magnesium isoglycyrrhizinate/compound armor soft liver tablets)for the treatment of hepatitis B ALT,AST,TBiL,ALB,LN,HA,PC-3,IV-C indicators improved better than the single drug(Silybum,meglumine,entecavir,lamivudine),the difference was statistically significant(P<0.05);The clinical efficacy of the Silybin meglumine tablets alone in preventing liver damage caused by anti-TB drugs or other drugs,the number of liver damage,and the adverse reaction index are better than the control group(biphenyl diester,inosine tablets,liver tyrol,glucurolactone,Huganning,Wei Hepatitis C alone or in combination),the difference was statistically significant(P<0.05);The clinical efficacy of Silybin meglumine tablets alone in the treatment of nonalcoholic fatty liver is better than that of the control group(Qizhi Rougan granule/glucurolactone),the difference was statistically significant(P<0.05).Conclusion The combination of Silybin meglumine tablets is effective in the treatment of hepatitis B,and the liver function index is improved obviously and the safety is good.It also has obvious advantages in preventing clinical effects of anti-tuberculosis drugs or other drugs
作者
王英
颜利玲
李娟
荣苑君
冯鑫
WANG Ying;YAN Li-ling;LI Juan(Zhuzhou Qianjin Pharmaceutical,Zhuzhou,Hunan 412007,China;Hunan Qianjin Xieli Pharmaceutical,Zhuzhou,Hunan 412007,China.)
出处
《中国处方药》
2020年第7期4-6,共3页
Journal of China Prescription Drug
